Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C

Name: Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C
Start: 2029-07-01

July 1, 2029

Company: Bicara Therapeutics Inc. (BCAX)
Drug: ficerafusp
Indication: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C — BCAX Phase 3 Readout | BioSniper